Oestrogen Receptor b and Neoadjuvant Therapy - Medical Science Assignment Help

Assignment Task:

Task:

In order to elucidate the relative importance of oestrogen receptor (ER)a, ERb and an ERb variant (ERb2/bcx) in the response of breast cancers to tamoxifen, tumour levels of each receptor were assessed in 36 patients before and after 3 months of neoadjuvant treatment with tamoxifen (20 mg daily). All patients were postmenopausal women presenting with large ERa-positive breast cancers. Clinical response to treatment was assessed by tumour volume changes as determined from sequential ultrasounds and pathological response by comparison of the tumour morphology before and after treatment. Of 33 cases, 23 (70%) were classified as having a clinical response and 16 (48%) as having a response pathologically. All tumours stained positively for ERa and ERb and 15 out of 33 (45%) for ERb2/bcx. There were no significant differences in quantitative expression of any receptor between tumours that subsequently responded and that did not, whether response was assessed clinically or pathologically. Tamoxifen treatment was associated with a decrease in ERa, but an increase was the most frequent change (17 out of 33) in ERb, and no consistent change was evident in staining of the ERb2/bcx variant. In summary, ERb1 and ERb2/bcx variant protein are detected in ERa-positive breast tumours but their expression is not associated with a response to tamoxifen. Differential changes in ERa and ERb were seen with treatment. British Journal of Cancer (2006) 94, 1333 – 1338. doi:10.1038/sj.bjc.6603082 www.bjcancer.com Published online 18 April 2006 & 2006 Cancer Research UK Keywords: breast; oestrogen receptor; 

The anti-oestrogen tamoxifen has a central place in the treatment of breast cancer. However, many tumours appear refractory to the drug and there is a need to discover predictive markers that can accurately identify hormone responsive tumours. In this setting, oestrogen receptor (ER)a is the single most informative marker, receptor-negative tumours rarely benefiting from endocrine therapy (Miller, 1996). However, although responses are largely restricted to ERa-positive tumours, only between 60 and 70% of these cancers shrink with treatment.

This Medical Science Assignment has been solved by our Medical Science Experts at My Uni Paper. Our Assignment Writing Experts are efficient to provide a fresh solution to this question. We are serving more than 10000+Students in Australia, UK & US by helping them to score HD in their academics. Our Experts are well trained to follow all marking rubrics & referencing style.

Be it a used or new solution, the quality of the work submitted by our assignment Experts remains unhampered. You may continue to expect the same or even better quality with the used and new assignment solution files respectively. There’s one thing to be noticed that you could choose one between the two and acquire an HD either way. You could choose a new assignment solution file to get yourself an exclusive, plagiarism (with free Turnitin file), expert quality assignment or order an old solution file that was considered worthy of the highest distinction.